On October 2, 2023, Knowledge Ecology International submitted written comments to the Centers for Medicare & Medicaid Services (CMS) in conjunction with the Medicare Price Negotiation public consultation process. CMS is hosting a series of patient-focused listening sessions this fall,… Continue Reading
KEI Notes on the Clinical Studies for Imbruvica (Ibrutinib) KEI Briefing Note 2023:3 October 2, 2023 James Love KEI-BN-2023-3
Notes on the Preclinical Development of Imbruvica (Ibrutinib) KEI Briefing Note 2023:4 October 2, 2023 Arianna Schouten KEI-BN-2023-4
United States of America Below are links to copies of the contracts entered into by the US government for technologies to combat the COVID-19 pandemic. KEI is updating this page as we gain access to more contracts, and less redacted… Continue Reading
On March 18, 2015, KEI, KEI Europe, and Essential Inventions submitted proposals for global voluntary licences for all patents necessary for hepatitis C (HCV) medicines to five drug companies — AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Merck.